I thought Mayes was touted as a guy who will close deals and create collaborations. He's been on board for three years.
It suggests that somebody with experience in the Pharmaceutical industry has the appropriate background to work at Advaxis.
We really have no idea how many big Pharmas have come calling. All we really know is Dan does not want to cash out early, meaning he wants full value for everything and so he is waiting to get that. That's it. It is very likely JNJ has called on Advaxis. They have an interest in Listeria vaccines and are a 15 minute drive away on Route 1.
You know, based on progressing to a Phase 3 with aim2cerv, and all of the many successes they have had, I would like to see them license a non-cancer construct...something they aren't even doing anything with, license it to somebody else to develop it and run the trial, and then they get a healthy cut. How about Zika or something that could use a timely response now.
Advaxis can raise money with another private placement or public offering. They have the unissued already authorized shares in the treasury and can raise money when needed. They don't have to ask for permission from anyone. Permission and alignment are two different things. While Dan does not need to seek permission he will absolutely want to seek alignment. There is no way Dan wants to anger institutions that own a big enough stake to make their voices heard and influence the direction of the BOD. The institutions are in mostly at double digit prices. The big difference between where Dan is today and where he was two years ago is the institutional shareholder base he so wanted to attract. Now that he has them, he has to keep them happy. This is the crossroads where a deal with Big Pharma OR a Dilutive offering arise as possibilities. We're waiting Dan, and obviously, the market is too.
I expect a slow gradual share price rise to the twenties over the next 3 months right smack in the middle of volatility. That's a fair price for the stock right now. Large existing Short position will certainly keep the stock volatile. While a slow gradual rise is expected, there will be lots of swings. BUY recommendations should be forthcoming. Hold your shares tight.